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Abstract 
 
Endothelial cells (EC), the cells that line blood vessels, can be activated by pro-
angiogenic cues and rearrange their cell-cell junctions to allow for sprouting angiogenesis. Bone 
morphogenetic protein (BMP) signaling plays a fundamental role in regulating angiogenesis and 
is pro-angiogenic through ligands BMP2 and BMP6. The BMP pathway is negatively regulated 
by SMAD6, an intracellular inhibitory SMAD. SMAD6 is anti-angiogenic and modulates EC 
adherens junction turnover both in vivo and in vitro. SMAD6 is comprised of two MAD 
homology domains, MH1 and MH2, which correlate to the N-terminal and C-terminal domains 
of the protein, respectively. The MH2 domain of SMAD6 is responsible for protein interactions 
important for its function, but the role of the MH1 domain is not understood. Here, I explore the 
function of the poorly characterized MH1 domain of SMAD6 in vitro by analyzing 
overexpression effects on BMP signaling outputs. I found that the MH1 domain is necessary for 
proper SMAD6 cellular localization, as its deletion led to SMAD6 mis-localization in the trans-
Golgi network. In the presence of BMP6 ligand, overexpression of either the MH1 or MH2 
domain alone did not inhibit BMP signaling nor maintain stable endothelial cell junctions to the 
degree of full-length SMAD6 overexpression. Collectively, my results demonstrate that the MH1 
domain of SMAD6 is important for proper localization of the SMAD6 protein, and localization 
is important for SMAD6 function. Numerous pathologies are associated with dysfunctional BMP 
signaling, and thus it is critical to fully understand the regulation of this pathway to inform future 
treatment. Therefore, understanding how the structure of SMAD6, a key inhibitor of BMP 
signaling, affects its function has significant therapeutic potential. 
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Introduction 
Angiogenesis, the growth of new blood vessels from pre-existing vasculature, forms the 
largest network in our bodies and is essential in many processes including embryogenesis and 
wound healing.1,2 Proper angiogenesis relies on the coordinated responses of pro-angiogenic 
signals and the interactions of endothelial cells (EC) through the establishment of cell-cell 
junctions such as tight and adherens junctions.3,4 However, under diseased conditions, 
angiogenesis can contribute to tumor growth by facilitating nutrient exchange through blood 
vessels.5 Therefore, due to its importance in development and contribution to the progression of 
cancer, understanding the regulation of angiogenesis is important. 
Bone morphogenetic protein (BMP) signaling, a member of the TGF-! superfamily, is 
known to regulate angiogenesis and is essential for the proper function of blood vessels.6,7,8 Our 
lab recently showed that BMP2 and BMP6 ligands are pro-angiogenic and increase blood vessel 
network complexity through regulation of lateral branching.9  BMP ligands bind to a hetero-
tetrameric receptor complex comprised of two type I and two type II serine/threonine kinase 
receptors.10,11 Ligand binding causes the type II receptor to phosphorylate and activate the type I 
receptor, which then phosphorylates intracellular receptor-associated SMAD proteins (R-
SMADs), SMADs 1/5/8, at the C-terminal tail sequence. This complex then binds to the 
common SMAD, SMAD4, and translocates into the nucleus to regulate transcription.12  
SMAD proteins are important intracellular signal transducers and transcriptional co-
modulators of BMP signaling that can either promote or inhibit angiogenesis. We showed that 
the intracellular inhibitory SMAD, SMAD6, is anti-angiogenic in vitro and in vivo.9,13 SMAD6 is 
thought to inhibit BMP signaling by competitively binding type I receptors or SMAD1/4 to 
inhibit SMAD1/5/8 phosphorylation or nuclear translocation, respectively.14 Our lab recently 
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discovered a novel role for SMAD6 in stabilization of EC junctions.13 Junctional rearrangement 
is one of the first things that must occur in order for sprouting angiogenesis to be induced. We 
showed that loss of SMAD6 leads to disorganized localization of VE-cadherin, the main EC 
adherens junction protein, and increased VE-cadherin internalization.13 VE-cadherin localization 
is used as a readout for activated versus quiescent EC, with activated junctions having serrated, 
punctate VE-cadherin localization between cells, whereas straight or linear VE-cadherin staining 
between cells is indicative of quiescent, stable EC.15 Increased VE-cadherin internalization also 
suggests that EC adherens junctions are less stable. BMP6 induces hyper-permeability and 
disruption of adherens junction by promoting VE-cadherin internalization.15 However, the 
mechanism whereby SMAD6 affects junctional stability is unknown, and it is unclear how 
distinct protein domains within SMAD6 contribute to its function. 
 SMAD proteins are comprised of two evolutionarily conserved MAD homology 
domains, MH1 and MH2 (MAD homology 1 and 2), separated by a non-conserved and variable 
proline-rich linker region that provides sites for non-TGF-	! receptor-driven 
phosphorylation.17,18,19 The N-terminal MH1 domain contains a DNA-binding motif, while the 
C-terminal MH2 domain is responsible for protein interactions, and it mediates the 
phosphorylation-triggered binding of  SMAD4 and R-SMADs.20,21,22 The MH2 domain is 
conserved in all SMADs and across species. However, the MH1 domain is poorly conserved 
across species and among the inhibitory SMADs.22 It is therefore possible that the MH1 domain 
(amino acids 148-275) of SMAD6 has cell-type specific functions, and thus, we aim to 
understand its function in EC.  
Several studies suggest that the MH1 domain of SMAD6 may be important for SMAD6 
function. SMAD6 can be methylated on arginine in the MH1 domain, which causes its removal 
 Ngo 5 
from the type I receptor, allowing BMP signaling to occur. This suggests that the MH1 domain 
may play an undiscovered role determined by post-translational modifications.23 Additionally, 
the full SMAD6 protein and not either domains alone is necessary for normal dorsal/ventral 
patterning of Xenopus embryos, which is controlled by BMP signaling early in development.24 
The relationship of the contribution of the MH1 domain to the primary known function of 
SMAD6 is thus in question, and is important to understanding the mechanism by which SMAD6 
functions in angiogenesis. 
While full-length SMAD6 suppresses BMP signaling, the importance of the MH1 domain 
in this inhibition is not well characterized. Thus, in the present study, I have sought to understand 
the poorly conserved MH1 domain of SMAD6 and its effect on BMP signaling with and without 
BMP6 ligand. I hypothesized that although the MH2 is traditionally considered the functional 
domain of SMAD6, the MH1 domain is necessary for BMP inhibition and contributes to 
unknown cell type specific functions.9 My results show that the MH1 domain is necessary for the 
localization of SMAD6, and that this localization is important for the full function of SMAD6 as 
mis-localization of SMAD6 correlated with inability to fully block signaling and to rescue 
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Materials and Methods: 
Cell Culture & Reagents:  
Human umbilical vein endothelial cells (HUVEC, Lonza C2519A) were maintained according to 
the manufacturer’s recommendations and were used in experiments from passages 2 to 4. 
HUVEC were grown in endothelial growth medium (EGM-2, Lonza CC-2535) with EC growth 
kit-VEGF (ATCC, PCS-100-041). All experiments were performed at ~85% confluency. 
 
Plasmids:  
To generate a plasmid expressing human SMAD6-tdTomato fusion protein with a doxycycline-
inducible promoter (pN1-hSMAD6-tdTomato),9 the full-length human SMAD6 (hSMAD6) 
coding sequence was amplified from pOTB7 hSMAD6 (GE Dharmacon MHS6278-202829590) 
using PrimeSTAR MAX polymerase (Clontech R045A) and the following primers: Forward: 
5’ATTCACAGATCTGCCACCATGTTCAGGTCCAAA-CGCTCG-3’, containing 6 nt 
overhang, BglII restriction site and Kozak consensus sequence, Reverse: 5’-ATTCACGGTA-
CCCTTCTGGGTTGTTGAGGAGGATCTC-3’, containing 6 nt overhang, KpnI restriction site 
and 1 nt deletion from stop codon for in-frame read-through to carboxy-terminal tdTomato tag. 
PCR product was purified and subcloned as described.9 
 
A plasmid expressing MH1-GFP (amino acids 1-275) fusion protein of SMAD6 was created by 
amplifying the MH1 domain from pN1- hSMAD6-tdTomato (generated earlier) with Phusion 
High-Fidelity polymerase (New England BioLabs M0530) and primers as following: Forward: 
5’- ATTCACAAGCTTGCCACCATGTTCAGGTCCAAACGCTCG-3’, containing 6 nt 
overhang and HindIII restriction site, Reverse: 5’-ATTCACGGATCCAGATTCGGGCCCG-
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CAGAG-3’, containing 6 nt overhang and BamHI restriction site. PCR product was run on a 1% 
TAE gel with ethidium bromide, purified using NucleoSpin kit (Clontech 740609), and double-
digested with HindIII (Life Technologies FD0504) and BamH1 (Life Technologies FD0054) 
restriction enzymes for 10 min at 37 ºC. pGFP-N1 empty vector (Clontech 632370) was digested 
with the same restriction enzymes, purified using NucleoSpin kit and de-phosphorylated for 5 
min at 37 ºC using FastAP Thermosensitive Alkaline Phosphatase (Life Technologies EF0654). 
Products were then ligated at a 3:1 (insert:vector) molar ratio using T4 Rapid Ligation Kit (Life 
Technologies K1422) for 10 min at 37 ºC. Products were then transformed in One Shot Top10 
competent cells (Invitrogen C4040-03), purified using Nucleospin Plasmid Kit (Clonetech 
740588.25), and sequenced. 
 
Generation of a plasmid expressing MH2-GFP (amino acids 321-496) fusion protein was created 
similarly to the generation of the plasmid with MH1-GFP. The MH2 domain of SMAD6 was 
amplified from pN1-hSMAD6-tdTomato (generated earlier) as a template with PrimeSTAR 
MAX polymerase and the following primers: Forward: 5’-ATTCACAAGCTTGCCACCA-
TGTCTCCGGACGCCACC-3’, containing 6 nt overhang and HindIII restriction site, Reverse: 
5’-ATTCACGGTACCCTTCTGGGTTGTTGAGGAGGATCTC-3’, containing 6 nt overhang, 
KpnI restriction site and 1 nt deletion from stop codon. PCR product was then run on 1% TAE 
gel with ethidium bromide, purified using NucleoSpin kit, and digested in parallel with pGFP-N1 
empty vector with HindIII and KpnI (Life Technologies FD054) restriction enzymes. Products 
were ligated similarly to the MH1-GFP plasmid at a 3:1 (insert:vector) molar ratio, transformed 
in Top 10 competent cells, and sequenced. 
 








Figure 1. Domain Constructs. Plasmid constructs of just the MH1 (orange) or the MH2 (green) 
domain compared to full-length SMAD6. The blue and black regions represent the variable and 
linker region, respectively. 
 
Plasmid DNA Transfections: 
HUVEC were transfected with each of the plasmid constructs (described above) using the 
standard Amaxa optimized protocol (Lonza VPB-1002). HUVEC (5 x 105 cells) were combined 
with 100 #L of Nucleotransfector solution and 2.5 #g of DNA and placed into a cuvette. The 
nucleofector program A-034 for HUVECs (Lonza VPB-1002) was applied and transfected cells 
were immediately transferred into EGM-2 media. HUVEC were then incubated at 37 ºC 
overnight before beginning next experiment. 
 
Immunofluorescence: 
HUVEC were seeded onto 0.1% gelatin coated coverslips overnight at 37 ºC, pretreated for 4 
hours in 0.1 % normal bovine calf serum (NBCS) in OptiMEM (Life Technologies 31985-070), 
and then treated for 90 min with either vehicle (4mM HCl + 0.5 % bovine serum albumin (BSA)) 
or recombinant human BMP6 (R&D Systems 507-BP-020) at 200 ng/mL in 0.1% NBCS + 
OptiMEM. Cells were then fixed for 10 min in 4% paraformaldehyde (PFA), washed 4 x 5 min 
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PBS. Cells were blocked for 1 hour at room temperature with the background suppression agent 
CAS-block (Life Technologies 00-8120) and then incubated in Rabbit anti-pSMAD1/5 primary 
antibody (1:1000, Cell Signaling 9516S) for phosphorylated SMAD1 and 5 (pSMAD1/5) 
immunofluorescence in CAS-block overnight at 4 ºC. For VE-cadherin, trans-Golgi, or cis-Golgi 
immunofluorescence, Rabbit anti-VE-cadherin (1:1000, Cell Signaling 2500S), Rabbit anti-
TGN46 (1:1000, Sigma SAB4200355), or Rabbit anti-GM130 (1:1000, Abcam ab52649) 
primary antibody were used, respectively. The following day, coverslips were washed 4 x 5 min 
with PBS, incubated with either goat anti-Rabbit Alexa Fluor 488 or 555 (1:500) secondary 
antibodies in CAS-block for 2 hours, and then incubated with DRAQ7 (1:250, Abcam, 
ab109202) in PBS for 10 min at room temperature. Coverslips were mounted on slides using 




H-pattern micropatterns (CYTOO 10-008-00-18) were placed in a 6-well plate and coated with 
5mg/mL fibronectin in PBS for 30 min at 37 ºC. Patterns were then washed with PBS and 
subsequently washed with EGM-2 media. HUVEC were then seeded at 15,000 cells/mL. Cells 
were allowed to attach to patterns at room temperature for 10 min before incubating at 37 ºC for 
20 min. Another EGM-2 wash was performed before allowing the cells to adhere overnight at 37 
ºC. Cells were then serum starved in 1% fetal bovine serum (FBS) in OptiMEM for 13 hours and 
treated with either vehicle or BMP6 as described above for 90 min at 37 ºC. The patterns were 
fixed and stained as described above for immunofluorescence using Rabbit anti-VE-cadherin 
primary antibody and DRAQ7. 
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Imaging and Quantification: 
All HUVEC fluorescent images were acquired on either an Olympus FV1200 Laser Scanning 
Confocal Microscope or Olympus FV3000 and FluoView software. FIJI (ImageJ) software was 
used for all analysis and quantification. pSMAD1/5 nuclear fluorescence intensities were 
determined on a single-cell basis using FIJI by measuring the mean gray values of pSMAD per 
nucleus. The brightest slice in the DRAQ7 (nuclear) channel from confocal z-stack images was 
threshold adjusted into a binary image (black nuclei, white background). Analysis was re-
directed to the pSMAD1/5 channel and the mean gray values per nucleus with a 50-500 #m2 was 
obtained.9 Similarly, quantification of the mean junctional VE-cadherin signal intensity was 
measured using the mean gray values of VE-cadherin. The VE-cadherin channel was adjusted 
into a binary image and mean gray values were measured within a 10 #m x 10 #m box over the 
middle of the junction. 
 
Analysis: 
All normalized datasets were graphed and analyzed using PRISM software. For two-sample data 
sets with equal variances, unpaired, two-tailed Student t-test was used. For data sets with greater 
than two conditions and equal variances, one-way analysis of variance (ANOVA) with Tukey’s 
post-hoc test was used to determine statistical differences with an alpha of 0.05. *P≤0.05, 
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Results 
The MH1 domain is necessary for proper localization of SMAD6.  
I first examined the effects of overexpression of MH1 or MH2 on SMAD6 localization. 
Although the MH2 domain inhibits BMP signaling, it is unclear if certain parts of SMAD6 
protein control its localization in the cell. I therefore hypothesized that the MH1 domain could be 
required for proper SMAD6 localization to the cell membrane. HUVEC were transfected with 
full-length SMAD6, MH1, or MH2 constructs and the subcellular localization of SMAD6 was 
examined by immunofluorescence. Endogenous SMAD6 is known to be punctate throughout the 
cell and extends to the cell membrane.9 However, examination of transfected ECs with the 
domain constructs 
showed that the 
MH2 mutant 




compared to full-length SMAD6 (Fig. 2A-C). The MH2 construct mainly demonstrated 
perinuclear localization (Fig. 2C). In contrast, the MH1 construct localized similarly to full-
length SMAD6, residing predominantly in the cytoplasm. These results suggest a novel role for 




Figure 2. MH1 domain is needed for localization of SMAD6. Transfection of 
HUVEC cells with either full-length SMAD6 (A), MH1 (B), or MH2 (C). 
 
A B C B 
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Closer examination of the perinuclear localization of the MH2 construct showed localization to 
the Golgi network. Specifically, the MH2 construct signal overlapped with the trans-Golgi 
network (Fig. 3A) more completely than with the cis-Golgi network (Fig. 3B). These findings 
suggest that the MH2 domain of SMAD6 is not sufficient to properly localize in EC without the 
MH1 domain and is instead stuck in the trans-Golgi apparatus.   
A 
B 
Figure 3. MH2 mutant protein is localized to the trans-Golgi network (TGN). HUVEC 
cells transfected with MH2 mutant protein and stained with either cis-Golgi marker (GM130) 
(A) or a trans-Golgi marker (TGN46) (B) and DRAQ7 (gray).  
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The MH1 and MH2 domains of 
SMAD6 are required for BMP 
signaling inhibition.  
I then examined levels of nuclear 
phosphorylated SMADs 1 and 5 
(pSMAD1/5) in transfected cells with 
and without the addition of BMP6 
ligand, as pSMAD1/5 signal in the 
nucleus can be used as a readout for 
BMP signaling. Treatment with BMP 
ligand induces BMP signaling and 
thus nuclear pSMAD1/5 localization. 
I reasoned that the MH2 domain alone 
should be able to inhibit BMP 
signaling, as it is thought to be the 
functional domain of the protein. 
However, because I saw that the MH1 
domain is required for SMAD6 
localization, I hypothesized that it is 
also required for SMAD6 full function 
in inhibition of BMP signaling. To test 
this, HUVEC were transfected with 
MH1, MH2, or MH1+MH2 constructs, 
A B C 
D E F 
G H I 
Merge 
Figure 4. Both MH1 and MH2 domains of SMAD6 are 
required for BMP6 signaling suppression via pSMAD 1/5 
nuclear localization. HUVEC cells transfected with full-length 
SMAD6 (A-C), MH1 (D-F), MH2 (G-I), and both MH1 and 
MH2 (J-L) mutant proteins with exogenous BMP6 and stained 
with pSMAD 1/5 antibody (red) and DRAQ7 (gray). Arrows 
point to transfected HUVEC cells. (M) Scatterplot of pSMAD 
1/5 nuclear fluorescent intensity of the different SMAD 
proteins. Graph represents 5 experiments. N=100 cells. 
  
L K J 
M 
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treated with either a vehicle or BMP6, and stained with pSMAD1/5 antibody. As expected, 
BMP6 treatment significantly increased overall nuclear pSMAD1/5 levels in transfected cells 
compared to controls (Fig. 4M). In the presence of BMP6 ligand, overexpression of full-length 
SMAD6 was found to decrease the expression of pSMAD1/5 significantly compared to the EV, 
indicating that full SMAD6 significantly inhibits BMP signaling. 30 However, the MH1 and MH2 
domain constructs only partially inhibited BMP signaling (Fig. 4M, compare dark blue and dark 
green to dark orange). Neither domain construct was able to inhibit pSMAD1/5 nuclear 
translocation to the degree of full-length SMAD6, suggesting that individual domains of SMAD6 
are not sufficient to inhibit BMP signaling. Thus, both the MH1 and MH2 domains of SMAD6 
are necessary for full BMP inhibition. In comparing pSMAD inhibition between the two domain 
constructs, the MH1 domain suppressed BMP signaling slightly better than the MH2 domain, 
(Fig. 4M, compare dark green to dark blue). Surprisingly, the overexpression of both the MH1 
and MH2 domain constructs together was able to suppress BMP signaling just as well as full-
length SMAD6 (Fig. 4M, compare dark orange to dark purple). This further suggests that both 
domains of SMAD6 are necessary for complete BMP inhibition, although it is unclear how the 
independent domains co-operate to restore SMAD6 function in EC. 
 
Full-length SMAD6 is required for EC adherens junction stability. We showed that 
knockdown of SMAD6 leads to disorganized VE-cadherin localization and increased VE-
cadherin internalization, indicative of activated EC.13 Additionally, signaling through BMP6 
increases VE-cadherin internalization in EC, modulating vascular permeability.16,25 Thus, I 
hypothesized that the overexpression of SMAD6 stabilizes endothelial cell junctions in the 
presence of BMP6 ligand. Furthermore, I hypothesized that this function of SMAD6 will require 
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both domains, and that neither MH1 or MH2 domains will stabilize junctions alone. EC that are 
quiescent have linear junctions whereas EC that are active exhibit serrated and/or punctate VE-
cadherin localization.15 To determine the effect of EV, SMAD6 and the different domain 
constructs on VE-cadherin localization, I transfected HUVEC with full-length SMAD6, MH1, 
and MH2 constructs and then plated them on cover slips or on H-pattern micropatterns to 
rigorously quantify the junctions between two EC. I stained with a VE-cadherin antibody to 
mark the adherens junction and then quantified the mean gray area of VE-cadherin at a cell-cell 
junction. In vehicle treated HUVEC, overexpression of full-length SMAD6 and the MH1 domain 
resulted in lower VE-cadherin area (Fig. 5A, C-F). Addition of BMP6 ligand resulted in a 
serrated pattern of VE-cadherin in ECs overexpressing EV, MH1, and MH2, indicative of 
adherens junctions that actively remodel and are therefore less stable (Fig. 5B, C-F), while EC 
transfected with full-length SMAD6 did not exhibit a BMP6-induced serrated phenotype (Fig. 
5G). Consistent with my hypothesis, these results suggest that both domains of SMAD6 are 
necessary for stable endothelial cell-cell junctions in vitro and are thus important for both BMP 














Figure 5. Both the MH1 and MH2 domains of SMAD6 are required for stable cell-cell junctions. 
Representative images of HUVEC cells transfected with EV, full-length SMAD6, MH1, and MH2 
constructs, stained for VE-cadherin (red) and nucleus (DRAQ7, gray) without (A) and with (B) exogenous 
BMP6. White boxes indicate areas of higher magnification. H-micropatterns of 2 cells transfected with EV 
(C), full-length SMAD6 (D), MH1 (E), or MH2 (F) with and without BMP6. (G) Quantification of mean 
junctional VE-cadherin signal intensity in endothelial cells between transfected cells using H-pattern 
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Discussion 
SMAD6 is a major intracellular inhibitory SMAD that limits BMP signaling, yet the 
precise structure-function relationships of this protein remain elusive.14,26 Collectively, my data 
indicate that the MH1 domain is necessary for the localization of SMAD6 in EC, and also for the 
inhibition of BMP signaling and EC adherens junctional stability. My studies show that the MH1 
domain of SMAD6 is particularly necessary for proper cellular localization, as overexpression of 
just the MH2 domain resulted in different localization than full-length SMAD6. This suggests 
that SMAD6 may be unable to be trafficked out of the trans-Golgi when it lacks the MH1 
domain. It is likely that, although the MH1 domain of SMAD6 is not conserved among species, 
there are certain amino acids and/or regions that are essential for SMAD6 trafficking and 
localization. However, additional functional studies are needed to determine which specific 
regions within the MH1 domain of SMAD6 that are required for proper protein localization. 
Interestingly, when MH1 or MH2 domains are overexpressed in the presence of BMP6, 
they were unable to suppress pSMAD1/5 signaling to the degree of full-length SMAD6. The 
MH2 domain of I-SMADs, such as SMAD6, participates in blocking downstream BMP signaling 
by competitively binding with type I receptors or SMAD1/4. Several important basic amino acid 
residues such as Lys-401 and Arg-409 in the MH2 domain of I-SMADs, particularly SMAD7, 
play an important role in receptor interactions.14,23,27 However, my results show that 
overexpression of just the MH2 domain was not sufficient in suppressing downstream BMP 
signaling compared to full-length SMAD6. Overexpression of the MH1 domain alone was also 
unable to rescue BMP signaling suppression, suggesting that the MH1 domain is necessary but 
not sufficient for SMAD6 function. It likely that the mis-localization of SMAD6 in cells with the 
MH2 construct decreased the ability of SMAD6 to bind to receptors and other SMADs. Thus, 
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though the MH2 domain is thought to be the functional domain for inhibiting BMP signaling, the 
localization and therefore inhibitory function of SMAD6 is in part, dependent on the MH1 
domain. Furthermore, HUVEC transfected with both MH1 and MH2 domain constructs 
significantly suppressed nuclear localization of pSMAD1/5 compared to EV. This suggests that 
the two separate domains may additively interact with each other to inhibit BMP signaling more 
sufficiently than either domain on its own.24 Though my results show that co-expression of the 
two domains can block downstream signaling, it is not clear how the two domains interact to 
accomplish this. Additional studies addressing this can help further characterize the role of the 
MH1 and MH2 domains of SMAD6 in BMP signaling.  
BMP signaling through BMP6 ligand increases internalization of VE-cadherin, and thus 
controls vascular permeability.16 Decreased barrier function is linked to hemorrhage of blood 
vessels.28 My results show that overexpression of full-length SMAD6, but not SMAD6 MH1 nor 
MH2, in the presence of BMP6 ligand led to decreased VE-cadherin area at the EC junction.  
This suggests that full-length SMAD6 is required to maintain junctional stability, and neither the 
MH1 nor the MH2 domain is sufficient to maintain this stability. Our lab recently showed that 
SMAD6 knockdown in HUVEC results in increased levels of phosphor-SRC, which is upstream 
of VE-cadherin internalization and EC activation.13 This is the first evidence that SMAD6 
influences function of the adherens junction protein VE-cadherin and Src.  
Though much work has been done in characterizing SMAD6, not much is known 
regarding its structure/function. The MH1 domain was poorly characterized and was thought to 
not contribute to SMAD6 function.27,29 My work, however, provides compelling evidence that 
the MH1 domain is required for the full functionality of the SMAD6 protein in BMP signaling, 
and thus, important in angiogenesis. Further analysis of interactions of domains with receptors 
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and junctional proteins will provide insight into the mechanism whereby SMAD6 stabilizes EC 
junctions. Understanding the structure/function of SMAD6 protein is critical to fully understand 
how it inhibits BMP signaling and how it regulates other cellular processes, such as adherens 
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